CASTLE ROCK, Colo., Feb. 12, 2015 /PRNewswire/ -- Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1® Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced that the Company will host an investor conference call to discuss business matters, including the recent FDA "Not Substantially Equivalent" response, on February 13, 2015, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
A live audio webcast will be accessible via the Investor Relations section of the Venaxis website, www.venaxis.com/webcast/. Participants and investors may also access the conference call by dialing 1-888-455-2260 (U.S.) or 1-719-457-2645 (Toll - International).
A replay of the call will be available approximately an hour after the end of the conference call on the Company's website. To access the webcast, please visit the investor relations section of the Venaxis website at www.venaxis.com/webcast/.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid blood based test for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low probability for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent, and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While the FDA clearance process and status is being evaluated, a limited commercial launch for the APPY1 Test is advancing in select European countries. For more information, visit www.venaxis.com.